FW: Formal analysis, Writing review & editing
Most lipoic acid supplements contain a racemic mixture of R -lipoic acid and S -lipoic acid (sometimes noted d,l -lipoic acid)
NICE has appraised its use within specialist weight management services, subject to BMI and eligibility criteria [12] Liraglutide (Saxenda) another licensed GLP-1 receptor agonist available for weight management in adults, subject to MHRA-approved indications and prescribing criteria Orlistat (Xenical/Alli) a lipase inhibitor available on NHS prescription and, at lower dose, over the counter Tirzepatide (Zepbound) a dual GIP/GLP-1 receptor agonist authorised by the MHRA specifically for chronic weight management in adults
Its proposed mechanism is to stimulate lipolysis (the breakdown of stored fat) and to inhibit lipogenesis (the formation of new fat), apparently through -adrenergic-related pathways, while unlike full-length GH not raising IGF-1 and not impairing glucose tolerance [1] [5]
Liraglutide (Saxenda) a GLP-1 receptor agonist licensed for weight management, with a more modest but clinically meaningful effect on body weight
With high odds ratios and large confidence intervals that suggest reduced precision because of the small sample size, the overall odds ratios from the random effects model (58.03) and the common effect model (57.57) both indicate a higher incidence of nausea over placebo ( Figure 6 )